A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study

Benjamin Speich1,2*, Ayodele Odutayo1,3, Nicholas Peckham1,4, Alexander Ooms1,4, Jamie R. Stokes1,4, Ramon Saccilotto5, Dmitry Gryaznov2, Belinda von Niederhäusern5,6, Bethan Copsey1, Douglas G. Altman1, Matthias Briel2,7 and Sally Hopewell1,4

Abstract
Background: To assess the quality of reporting of RCT protocols approved by UK research ethics committees before and after the publication of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline.

Methods: We had access to RCT study protocols that received ethical approval in the UK in 2012 (n=103) and 2016 (n=108). From those, we assessed the adherence to the 33 SPIRIT items (i.e. a total of 64 components of the 33 SPIRIT items). We descriptively analysed the adherence to SPIRIT guidelines as proportion of adequately reported items (median and interquartile range [IQR]) and stratified the results by year of approval and sponsor.

Results: The proportion of reported SPIRIT items increased from a median of 64.9% (IQR, 57.6–69.2%) in 2012 to a median of 72.5% (IQR, 65.3–78.3%) in 2016. Industry-sponsored RCTs reported more SPIRIT items in 2012 (median 67.4%; IQR, 64.1–69.4%) compared to non-industry-sponsored trials (median 59.8%; IQR, 46.5–67.7%). This gap between industry- and non-industry-sponsored trials increased in 2016 (industry-sponsored: median 75.6%; IQR, 71.2–79.0% vs non-industry-sponsored: median 65.3%; IQR, 51.6–76.3%).

Conclusions: The adherence to SPIRIT guidelines has improved in the UK from 2012 to 2016 but remains on a modest level, especially for non-industry-sponsored RCTs.

Keywords: Randomised controlled trial, Reporting quality, Trial protocol, Meta-research

Background
Randomised controlled trials (RCTs) provide the highest level of evidence when assessing the potential benefits and potential harms of health care interventions [1, 2]. As the conduct of RCTs is complex, a study protocol describing the essential steps and justification for the trial is needed for efficient and successful completion of a trial [3, 4]. Protocols are not only crucial so that the involved study team has clear guidance about the exact study process; they are also necessary so that external parties, such as funding agencies, research ethics committees, regulatory agencies, medical journals, and systematic reviewers can evaluate the conduct of the study [5]. A meta-research study conducted by Getz and colleagues found that by putting greater attention to study protocols, approximately a third of all protocol
The SPIRIT recommendations in 2013, a checklist included the goal of improving the reporting. The initiative published also clearly define how data is analysed to avoid selective trial protocols that were approved in 2012 and 2016. Research ethics committees, granted us access to clinical trial protocols before and after the publication of the SPIRIT guidelines. Due to different timelines, as indicated in our protocol, the analyses of the ASPIRE sample from Switzerland, Canada, and Germany (ASPIRE-SCAGE) were published earlier. In this study, we assess now if there was an improvement in adherence to SPIRIT guidelines in RCT protocols from the UK (ASPIRE-UK).

Methods

The international ASPIRE project aims to assess in a repeated cross-sectional design the completeness of RCT protocols before and after the publication of the SPIRIT reporting guidelines. The detailed methods used for this study and the results from ASPIRE-SCAGE were reported previously; here, we report the results for ASPIRE-UK. Additional ASPIRE substudies evaluated the fate of RCTs in terms of registration, discontinuation, and non-publication, the completeness of reporting in protocols of regulated and non-regulated interventions, the use of routinely collected data and patient-reported outcomes, as well as the planning of sub-group analysis in study protocols.

Selection of included protocols of randomised controlled trials

After signing a confidentiality agreement the UK Health Research Authority and Bristol regional research ethics office, which is responsible for 19 research ethics committees, granted us access to clinical trial protocols that were approved in 2012 and 2016 for this study. We included studies that evaluated the effect of an intervention on clinical outcome measures in the frame of a RCT. As units of randomisation, we considered different individuals, groups (cluster-trials), or within individuals (split-body design). We excluded phase 1 trials, feasibility and pilot studies, studies to which we had no access to the full trial protocol, protocols describing more than one RCT, and studies evaluating primarily health economics. Available study protocols were checked for eligibility by one author (2012: AyodeleO; 2016: BS). In 2016 more RCT protocols were available than in 2012; hence, a random sample of protocols was included in 2016 to match the sample size of 2012. We selected the years 2012 and 2016 for our assessment because 2012 should be representative for the completeness of reporting in the study protocol 1 year before SPIRIT was published, while 2016 was chosen to provide sufficient time so that stakeholders (e.g. researchers, funders, ethical committees) can get familiar with the new reporting guideline.

Data extraction

The SPIRIT checklist includes 33 items that should be reported. To operationalise the assessment of the items this list can be further divided into different components that should be reported to fulfil the item. The 33 items from the SPIRIT checklist can be divided into a total of 270 components. To operationalise the checklist for data extraction the ASPIRE-project team (AyodeleO; BN; SH; MB and DGA) selected the 64 components that were deemed most crucial (at least one from each of the 33 items) that should be reported (see Appendix 1 for selection of 64 components and rational). We extracted the following information from study protocols: Target sample size, sponsorship (industry- vs non-industry-sponsored), number of trial arms, number of study centres, number of countries where the trial was conducted, hypothesis (superiority vs non-inferiority), and the adherence to the 64 components of the 33 items from the SPIRIT checklist. The data extraction was piloted by several members of the ASPIRE team and everyone involved underwent a calibration process. Data extraction for ASPIRE-UK was conducted by one person (2012: AyodeleO, BC; 2016: BS) and 30% of 2012 and 2016 protocols were double extracted by a second reviewer (2012: BS; 2016: NP, AlexO, JRS). Disagreements were resolved by discussion. Agreement between the data extraction performed by the data extractors was generally high with a median of 6% (interquartile ranges [IQR]: 5–11%) of items needing to be changed due to the second extractor (2012: 8%; IQR: 4–11%; 2016: 6%; IQR: 5–9%).
Analysis
We descriptively assessed the number and the proportion of adequately reported SPIRIT items (as median and IQR) in trial protocols approved in 2012 and 2016. The main approach, as defined in our design paper, allowed “for partial credit of individually met subitems or components of major SPIRIT items” [17]. If there was, for example, an item with four components that were included in our extraction, each fulfilled component scored 0.25 points. Sensitivity analyses were conducted for the other two pre-specified approaches rating an item only if all components were met, or rating each component one point (see design paper for further details [17]), and for assigning no points to not applicable items (vs. giving points when the item was not applicable). Analyses were stratified by year of study approval (2012 vs 2016) and by sponsor (industry- vs non-industry-sponsored).

In three separate analyses, we highlight (i) selected SPIRIT item components that achieved an absolute increase in reporting from 2012 to 2016 above 20%, (ii) absolute increase in reporting from selected SPIRIT item components from 2012 to 2016 for components that achieved low reporting (i.e. \( \leq 50\% \)) in 2012, and (iii) selected SPIRIT components for which the reporting was still poor (<60%) in 2016. We conducted beta regression analyses to assess if year of protocol approval, type of sponsor, sample size (in increments of 1000), or multicentre trials were associated with higher adherence to SPIRIT guidelines. All analyses were conducted using STATA 16.1 [21].

Results
We included 211 study protocols of approved RCTs (103 in 2012, 108 in 2016; Fig. 1). The included trials had a median planned sample size of 200 (IQR 90–400) and approximately half were industry-sponsored trials (52.6%; 111/211). Overall, the majority of RCT protocols were 2-arm studies (74.9%; 158/211). Most protocols were of superiority trials (84.8%; 179/211), and there were more protocols for studies conducted at multiple study centres (76.3%; 161/211; Table 1).

The proportion of adequately reported SPIRIT items increased from 64.9% (IQR: 57.6–64.9%) in 2012 to 72.5% (IQR: 65.3–78.3%) in 2016 (Table 2). This translates to a median of 21.4 (IQR: 19.0–22.8), and 23.9 (IQR: 21.6–25.8) correctly reported SPIRIT items in 2012 and 2016, respectively. The proportion of adherence to reporting guidelines was higher in 2012 for industry-sponsored trials (67.4%; IQR 64.1–69.4%) compared to non-industry-sponsored RCTs (59.8%; IQR: 46.5–67.7%). This difference was even larger in 2016 (industry-sponsored: 75.6%; IQR 71.2–79.0%; non-industry-sponsored: 65.3%; IQR: 51.6–76.3%; Fig. 2). All the conducted sensitivity analyses confirmed that the reporting improved in 2016 and was in general better in industry-sponsored RCTs (see supplementary Table S1, appendix).

The reporting for all 33 SPIRIT items, consisting of the 64 extracted components, are reported in Table S2 (Appendix). A total of 12 selected SPIRIT item components had an absolute increase in adequate reporting above 20% (Table 3). The highest increase was seen for
components belonging to item 28 “Declaration of Interests” (absolute increase: 53.1%; 2012: 11.7%; 2016: 64.8%), item 30 “Ancillary and post-trial care” (absolute increase: 43.9%; 2012: 11.7%; 2016: 55.6%), and item 19 “Data entry and coding” (absolute increase: 45.2%; 2012: 18.7%; 2016: 63.9%). A total of 21 selected SPIRIT item components had relatively low reporting in 2012 (i.e. ≤50%), with some items showing no indication for improvement (i.e. “Name of protocol contributors/authors, “Eligibility criteria for study centres and who will perform the intervention”, “Location of participant recruitment”, “Person who will enrol/assign participants”; Table S3). In 2016, we still identified an overall adherence to reporting guidelines in 2016 below 60% for 18 out of the 64 selected SPIRIT item components (Table 4). The components that were least often reported belonged to item 31c “Plans for

Table 1 Baseline characteristics of study protocols from randomised controlled trials that were ethically approved in 2012 or 2016

|                          | 2012 (n=103) | 2016 (n=108) | Total (n=211) |
|--------------------------|--------------|--------------|---------------|
| Target sample size, median (IQR) | 180 (90-430) | 222 (93-391) | 200 (90-400) |
| Sponsorship              |              |              |               |
| Industry-sponsored       | 49 (47.6%)   | 62 (57.4%)   | 111 (52.6%)   |
| Non-industry-sponsored   | 54 (52.4%)   | 46 (42.6%)   | 100 (47.4%)   |
| Number of trial arms     |              |              |               |
| 2 arms                   | 76 (73.8%)   | 82 (75.9)    | 158 (74.9%)   |
| 3 arms                   | 17 (16.5%)   | 16 (14.8%)   | 33 (15.6%)    |
| 4 arms                   | 7 (6.8%)     | 7 (6.5%)     | 14 (6.6%)     |
| >4 arms                  | 3 (2.9%)     | 3 (2.8%)     | 6 (2.8%)      |
| Centres                  |              |              |               |
| Single-centre            | 25 (24.3%)   | 22 (20.4%)   | 47 (22.3%)    |
| Multicentre              | 77 (74.8%)   | 84 (77.8%)   | 161 (76.3%)   |
| Unclear                  | 1 (1.0%)     | 2 (1.9%)     | 3 (1.4%)      |
| Countries                |              |              |               |
| National                 | 61 (59.2%)   | 45 (41.7%)   | 106 (50.2%)   |
| International            | 42 (40.8%)   | 63 (58.3%)   | 105 (48.8%)   |
| Hypothesis               |              |              |               |
| Superiority              | 84 (81.6%)   | 95 (88.0%)   | 179 (84.8%)   |
| Non-inferiority          | 11 (10.7%)   | 8 (7.4%)     | 19 (9.0%)     |
| Superiority and non-inferiority | 2 (1.9%) | 0 (0.0%) | 2 (1.0%) |
| Unclear/not labelled in this regard | 6 (5.8%) | 5 (4.6%) | 11 (5.2%) |

Abbreviations: IQR interquartile range

Table 2 Adherence to SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) reporting guidelines in randomised clinical trials that received ethical Approval in 2012 and 2016, respectively

|                          | 2012 (n=103) | 2016 (n=108) | Total 2012 (n=211) | 2012 (n=103) | 2016 (n=108) | Total 2016 (n=211) |
|--------------------------|--------------|--------------|--------------------|--------------|--------------|--------------------|
| SPIRIT items (n=33) adequately reported (median; IQR)* | 22.5 (20.8–22.9) | 19.8 (15.3–22.3) | 21.4 (19.0–22.8) | 25.0 (23.5–26.1) | 21.5 (17.0–25.2) | 23.9 (21.6–25.8) |
| Proportion of SPIRIT items adequately reported (median; IQR) | 67.4% (64.1–69.4%) | 59.8% (46.5–67.7%) | 64.9% (57.6–69.2%) | 75.6% (71.2–79.0%) | 65.3% (51.6–76.3%) | 72.5% (65.3–78.3%) |

* Using the “major item approach” in which adequately reported components of items receive partial credit. See design paper for more details about individual approach [17] and appendix Table S1 for sensitivity analyses using other pre-defined approaches
granting access to full trial protocol” (7.4%; 8/108), item 5a “Names of protocol contributors/authors” (11.1%; 12/108), and item 29 “Who will have access to full dataset” (23.2%, 25/108). Conducting a multivariable beta regression showed that the following variables were associated with higher completeness of reporting: ethical approval in 2016 (vs 2012), industry sponsorship (vs non-industry sponsorship), and multicentre RCTs (vs. single centre, Table S4).

Discussion
The results of our study showed that the proportion of reported SPIRIT items in RCT study protocols approved by UK research ethics committees increased between 2012 and 2016. This improvement was most evident in industry-sponsored studies which reached an improvement of more than 10%. Nevertheless, large deficiencies in the reporting of important SPIRIT items remain, given that industry-sponsored studies report 1 out of 4 (24.4%) SPIRIT items inadequately and non-industry-sponsored RCTs miss to report 1 out of 3 items (34.7%).

Our results are in line with an assessment conducted by Kyte and colleagues on a sample of 75 non-industry-sponsored RCTs from the UK National Institute for Health Research Health Technology Assessment that were approved in 2012 and 2013 [22]. They concluded that 63% of SPIRIT items were adequately reported which is comparable to the 60% we identified in non-industry-sponsored RCTs approved in 2012. The part of the ASPIRE study [17] that assessed the completeness of reporting of study protocols in Switzerland, Canada, and Germany (published previously due to different timelines of available resources) found similar adherence to SPIRIT guidelines for industry-sponsored RCTs in 2016 as within the UK sample (ASPIRE-SCAGE: 77% [18]; ASPIRE-UK: 76%). However, it appeared that the reporting in Switzerland, Canada, and Germany had a greater improvement in non-industry-sponsored trials (from 64% in 2012 to 76% in 2016) compared to the sample in the UK (from 60% in 2012 to 65% in 2016). In ASPIRE-SCAGE the strongest improvement in completeness of reporting in non-industry-sponsored RCTs was seen in trials approved by Swiss ethics committees [18]. It is possible that the SPIRIT-based protocol template [23] that was introduced by Swiss ethics in the frame of the new Swiss legislation on human research in 2014, might be related to this improvement (e.g. providing guidance for researchers on how to write a protocol). This approach was also implemented by the journal Trials, as they provide a template following closely all SPIRIT items, aiming to make protocols more structured [24]. The Health Research Authority from the UK has also provided an optional template in 2016 [25]. An additional assessment of completeness of reporting in study protocols (e.g. from 2020) is needed to assess if this intervention
Table 3  Selected SPIRIT item components with highest absolute improvement in adequate reporting (2016 vs 2012)

| SPIRIT component | Belonging to SPIRIT Item Number | 2012 | 2016 | Absolute increase |
|------------------|--------------------------------|------|------|-------------------|
|                  | Industry sponsorship (n=49) | Non-industry sponsorship (n=54) | Total 2012 (n=103) | Industry sponsorship (n=62) | Non-industry sponsorship (n=46) | Total 2016 (n=108) |
| Basic study design in title | 1 | 31 (63.3%) | 9 (16.7%) | 40 (38.8%) | 53 (85.5%) | 24 (52.2%) | 77 (71.3%) | 32.5% |
| Name and contact details of sponsor | 5b | 12 (24.5%) | 16 (29.6%) | 28 (27.2%) | 31 (50.0%) | 31 (67.4%) | 62 (57.4%) | 30.2% |
| Steering Committee General Membership and Role | 5d | 35 (71.4%) | 45 (83.3%) | 81 (77.7%) | 56 (90.3%) | 39 (84.8%) | 73 (98.0%) | 20.3% |
| Research question described and justified | 6a | 11 (22.5%) | 9 (16.7%) | 2NA | 20 (19.4%) | 35 (56.5%) | 13 (28.3%) | 48 (44.4%) | 25.0% |
| Strategies to improve or monitoring of adherence | 11c | 33 (67.4%) | 34 (63.0%) | 67 (65.1%) | 57 (91.9%) | 40 (87.0%) | 97 (89.8%) | 24.7% |
| Of which not applicable | | 9 (18.4%) | 25 (46.3%) | 34 (33.0%) | 23 (37.1%) | 28 (60.9%) | 51 (41.2%) | |
| Expected recruitment rate | 15 | 7 (14.3%) | 15 (14.3%) | 22 (21.4%) | 20 (32.3%) | 25 (45.4%) | 45 (41.7%) | 20.3% |
| Method for generation of random sequence | 16a | 21 (42.8%) | 29 (53.7%) | 50 (48.5%) | 51 (82.3%) | 30 (65.2%) | 81 (75.0%) | 26.5% |
| Strategies to promote participant retention and complete follow-up | 18b | 9 (18.4%) | 20 (38.0%) | 29 (28.4%) | 38 (61.3%) | 16 (34.8%) | 54 (50.0%) | 21.6% |
| Of which not applicable | | 2 (4.1%) | 2 (3.7%) | 4 (3.9%) | - | - | - | |
| Data entry and coding | 19 | 11 (22.5%) | 9 (15.5%) | 20 (18.7%) | 49 (79.0%) | 20 (43.5%) | 69 (63.9%) | 45.2% |
| Process for making amendments described | 25 | 27 (55.1%) | 8 (14.8%) | 35 (34.0%) | 50 (80.7%) | 21 (45.7%) | 71 (65.7%) | 31.7% |
| Declaration of Interests | 28 | 8 (16.3%) | 4 (7.4%) | 12 (11.7%) | 60 (96.8%) | 10 (21.7%) | 70 (64.8%) | 53.1% |
| Ancillary and post-trial care | 30 | 4 (8.2%) | 8 (14.8%) | 12 (11.7%) | 29 (46.8%) | 31 (67.4%) | 60 (55.6%) | 43.9% |

has improved adherence to the SPIRIT Statement. In order that well-reported study protocols are useful to others (e.g. other researchers, patients, funding bodies), they should also be publicly available. In our sample, only 6% of protocols clarified who will have access to the final study protocol. Hence, it is important that not only the completeness of reporting of study protocols is improved, but also the public sharing of protocols is actively promoted [26] (or even enforced in parallel by journals publishing the results). Other important aspects to increase transparency include increasing the rate of registered trials and published trials which we have assessed in the frame of the ASPIRE project [17] and published in a separate sub-study [19, 27].
The following limitations should be noted: First, given the high workload of extracting all 64 components from ethically approved study protocols and due to limited resources, only approximately 30% of studies were extracted in duplicate. In addition, study protocols from 2012 (AO) and 2016 (BS) were extracted separately by different main extractors. We tried to control for this limitation by conducting pilot assessments and conducting calibration extractions so that extractors use the same judgement when assessing the SPIRIT items. The agreement between data extractors was relatively high with only around 6% of items needed to be revised after double extraction. However, we cannot fully exclude that this limitation might have influenced our study results. Second, some of the SPIRIT items assessed were always by default fulfilled as the RCT received already ethical approval (i.e. items “research ethical approval”, “consent form provided”). We do not believe that this could have influenced the overall study results. Third, the SPIRIT checklist is a guidance for writing, supporting authors to implement the most essential information in a manuscript. It was, however, not developed as a measurement tool to assess reporting quality [28]. As the SPIRIT checklist includes 33 items consisting of 270 components we had to operationalise the checklist to be able to extract data in a meaningful way (see study protocol and for more details [17] and Appendix 1 for selection of 64 components). Even though we conducted different sensitivity analyses how to credit individual components (supplementary Table S1, appendix), as pre-defined in our study protocol [17], showing all the same overall result, we cannot completely exclude the possibility that selecting different components, to operationalise the assessment of complete reporting, might have influenced our results. Fourth, our study cannot clarify if the improvement in reporting is due to the publication of the SPIRIT guidelines. Other factors, such as the awareness of the importance of study protocols and transparent reporting in general, as well as better knowledge and knowledge transfer in RCT methodology amongst clinical scientists, might have also influenced the study result.

In conclusion, adherence to SPIRIT guidelines has improved in the UK from 2012 to 2016 but remains on a modest level, especially for non-industry-sponsored RCTs. Protocol templates closely aligning with the SPIRIT guidelines might be a way to further improve the reporting in trial protocols.

### Table 4

| SPIRIT component | Belonging to SPIRIT Item Number | Industry sponsorship (n=62) | Non-industry sponsorship (n=46) | Total 2016 (n=108) |
|------------------|--------------------------------|-----------------------------|-------------------------------|-----------------|
| Names of protocol contributors/authors | 5a | 5 (8.1%) | 7 (15.2%) | 12 (11.1%) |
| Name and contact details of sponsor | 5b | 31 (50.0%) | 31 (67.4%) | 62 (57.4%) |
| Research question described and justified | 6a | 35 (56.5%) | 13 (28.3%) | 48 (44.4%) |
| Countries where data will be collected listed | 9 | 9 (14.5%) | 36 (78.3%) | 45 (41.7%) |
| Eligibility criteria for study centres and who will perform the intervention | 10 | 8 (12.9%) | 24 (52.2%) | 32 (29.6%) |
| Sample size: assumed values for outcome | 14 | 41 (36.9%) | 20 (43.5%) | 61 (56.5%) |
| Location of participant recruitment | 15 | 7 (11.3%) | 36 (78.3%) | 43 (39.8%) |
| Person(s) who will recruit participants | 15 | 5 (8.1%) | 31 (61.4%) | 36 (33.3%) |
| Expected recruitment rate | 15 | 20 (32.3%) | 25 (45.4%) | 45 (41.7%) |
| Person who will enrol/assign participants | 16c | 12 (19.4%) | 17 (37.0%) | 29 (26.7%) |
| Personnel who will collect data | 18a | 19 (30.7%) | 24 (52.2%) | 43 (39.8%) |
| Strategies to promote participant retention and complete follow-up | 18b | 38 (61.3%) | 16 (34.8%) | 54 (50.0%) |
| DMC is planned or why it is not planned | 21a | 41 (66.1%) | 22 (47.8%) | 63 (58.3%) |
| Audits/external monitoring described | 23 | 26 (41.9%) | 3 (5.5%) | 29 (26.9%) |
| Who will have access to full dataset | 29 | 18 (29.0%) | 7 (15.2%) | 25 (23.2%) |
| Plans to disseminate trial results to key stakeholders/publication provided | 31a | 29 (46.8%) | 31 (67.4%) | 60 (55.6%) |
| Authorship eligibility criteria | 31b | 23 (37.1%) | 15 (32.6%) | 38 (35.2%) |
| Plans for granting access to full trial protocol | 31c | 6 (9.7%) | 2 (4.4%) | 8 (7.4%) |
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13063-022-06516-1.

Additional file 1: Appendix 1. The 64 components that were extracted to assess adherence of the 33 SPIRIT items (as defined for the ASPIRE project) in Table S1. Sensitivity analysis using different approaches to assess the adherence to SPIRIT guidelines. Table S2. Adherence to individual SPIRIT items stratified by year and sponsorship. Table S3. Absolute increase in adequate reported selected SPIRIT item components (2012 vs 2016) for components that were not commonly reported (i.e. ≤50%) in 2012. Table S4. Results from beta regression to assess what characteristics are associated with higher proportion of adequate reporting.

Acknowledgements

We thank the UK Health Research Authority and Bristol regional research ethics office for their support with conducting this study and for granting us access to approved study protocols from 2012 and 2016. We are grateful to Prof. Doug Altman (Centre for Statistics in Medicine, University of Oxford) who initially conceived the concept of the Adherence to SPIRIT ReCommendations (ASPIRE) study and who sadly died before it was completed.

Public involvement

We did not involve patients or the public in this meta-research study.

Authors’ contributions

Ayodele O, BvN, MB, DGA and SH conceived of the study. Ayodele O, BS and RS developed the tool for data extraction. BS, AODutayo, DG, BvN, MB and SH piloted the data extraction tool. BS, Ayodele O, BP, ALEXO, BC and JRS extracted the data. BS and Ayodele O analysed the data. BS wrote the first draft of the manuscript. All authors critically revised the manuscript and approved the final version.

Funding

Benjamin Speich is supported by an Advanced Postdoc Mobility (P300PR_177933) and a Return Postdoc Mobility (P4P4PM_194496) grant from the Swiss National Science Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The collaborating research ethic committee granted us access to approved study protocols under the condition that only aggregated data will be published. Hence, no individual data will be shared for this project.

Declarations

Ethics approval and consent to participate

The study did not include any human participants, human data or human tissue. The UK Health Research Authority and Bristol regional research ethics office is a project partner of the conducted meta-research study. They are responsible for 19 research ethics committees and granted us access to approved study protocols.

Consent for publication

Not applicable.

Competing interests

BvN contributed to the ASPIRE project as part of her PhD thesis before her current employment with Roche (her current employer had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript).

DG contributed to the ASPIRE project as part of his PhD thesis before his current employment with Idorsia Pharmaceuticals Ltd (his current employer had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript). All authors have declared that no competing interests exist.

Author details

1 Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 2 Meta-Research Centre, Department of Clinical Research, University Hospital Basel, University of Basel and University Hospital Basel, Basel, Switzerland. 3 Roche Pharma AG, Grenzach-Wyhlen, Germany. 4 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.

Received: 29 November 2021   Accepted: 5 July 2022
Published online: 27 July 2022

References

1. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10.
2. Murad MH, Asl N, Alhasaw M, Alhada B. New evidence pyramid. Evid Based Med. 2016;21(4):125–7.
3. Declaration of Helsinki, Version October 2013. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ (Accessed: 8 Dec 2020).
4. Vijayananthan A, Nawawi O. The importance of good clinical practice guidelines and its role in clinical trials. Biomed Imaging Interv J. 2008;4(1):e5.
5. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
6. Getz KA, Stergiopoulos S, Short M, Surgeon L, Krauss R, Pretorius S, et al. The impact of protocol amendments on clinical trial performance and cost. The Innov Regul Sci. 2016;50(4):436–41.
7. Getz KA, Zuckerman R, Crap AL, Hidie AK, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inform J. 2011;45(3):265–75.
8. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ. 2008;337:a2299.
9. Tetzlaff JM, Chan AW, Kitchen J, Sampson M, Tricco AC, Moher D. Guideline for randomized clinical trial protocol content: a systematic review. Syst Rev. 2012;1:43.
10. Scharf O, Coles AV. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24(2):3933–8.
11. Pildal J, Chan AW, Hrobjartsson A, Forfang E, Altman DG, Gotzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330(7499):1049.
12. Hrobjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gotzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. J Clin Epidemiol. 2009;62(9):967–73.
13. Chan A, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291(20):2457–65.
14. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the lancet. Lancet. 2008;372(9634):201.
15. Smyth RM, Kirkham JJ, Jacoby A, Altman DG, Gamble C, Williamson PR. Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. BMJ. 2011;342:c7153.
16. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Kirela-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.
17. Gryaznov D, Dutayo A, von Niederhausern B, Speich B, Kasenda B, Ojeda-Ruiz E, et al. Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the adherence to SPIRIT ReCommendations (ASPIRE) study and associated projects. Trials. 2020;21(1):896.
18. Gryaznov D, von Niederhausern B, Speich B, Kasenda B, Ojeda-Ruiz E, Blumle A, et al. Reporting quality of clinical trial protocols: a repeated cross-sectional study about the adherence to SPIRIT recommendations.
in Switzerland, CANada and GErmany (ASPIRE-SCAGE). BMJ Open. 2022;12(5):e053417.

19. Speich B, Gryaznov D, Busse JW, Lohner S, Klatte K, et al. Non-registration, discontinuation, and nonpublication of randomized trials: a repeated meta-research analysis. PLoS Med. 2022;19(4):e1003980.

20. Lohner S, Gryaznov D, von Niederhausern B, Speich B, Kasenda B, Ojeda-Ruiz E, et al. Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: a repeated cross-sectional study. J Clin Epidemiol. 2021;139:340-349. https://pubmed.ncbi.nlm.nih.gov/34029678/.

21. StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC; 2019.

22. Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, et al. Systematic evaluation of the patient-reported outcome (PRO) content of clinical trial protocols. PLoS One. 2014;9(10):e110229.

23. Swissethics. Swiss Association of Research Ethics Committees. Study protocols. https://swissethics.ch/en/templates/studienprotokollvorlagen (Accessed: 22 Apr 2022).

24. Treweek S. Protocols-more structure, less 'Wuthering Heights.' Trials. 2019;20(1):649.

25. NHS Health Research Authority. Protocol guidance and template for use in a CTIMP: consultation. (Accessed: 3 Sep 2021).

26. Sender D, Clark J, Hoffmann TC. Analysis of articles directly related to randomized trials finds poor protocol availability and inconsistent linking of articles. J Clin Epidemiol. 2020;124:69–74.

27. Speich B, Gryaznov D, Busse JW, Lohner S, et al. Non-registration, discontinuation, and non-publication of randomized trials: a repeated meta-research analysis. PLoS Med. 2022; (in press).

28. Logullo PA-O, MacCarthy A, Kirtley S, Collins GS. Reporting guideline checklists are not quality evaluation forms: they are guidance for writing. Health Sci Rep. 2020;3(2):e165. https://pubmed.ncbi.nlm.nih.gov/32373717/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.